Elizabeth Brooks Claus PhD, MD
Professor of Public Health (Biostatistics); Director of Medical Research, School of Public Health
Elizabeth B. Claus, Ph.D., M.D., is Professor and Director of Medical Research in the Yale University School of Public Health as well as Attending Neurosurgeon within the Department of Neurosurgery at the Brigham and Women’s Hospital. She is a past permanent member of the NIH Epidemiology and Disease Control Study Section II (Epidemiology of Cancer) and a member of the board of advisors for the Central Brain Tumor Registry of the United States (CBTRUS), the Acoustic Neuroma Association, and the Brain Tumor Epidemiology Consortium. Dr. Claus' work is focused in cancer and genetic epidemiology with an emphasis on the development of risk models and outcome prediction for breast and brain tumors. Dr. Claus was the PI of the statewide case/control study of breast carcinoma in-situ (DCIS) of 1000 cases and 1000 controls as well as the follow-up and mammographic breast density studies of this same group of women. She is the overall PI of the Meningioma Consortium, the Meningioma Genome-Wide Association Study and the Yale Acoustic Neuroma Study. She is co-investigator of the GLIOGENE (Genes for Glioma) and International Glioma Case/Control project. In these studies she is working to define genetic and environmental risk factors for brain tumors. In addition to her research activities, Dr. Claus trained as a neurosurgeon at Yale-New Haven Hospital and completed a fellowship in neurosurgical oncology at Brigham and Women’s Hospital; her clinical focus is on the surgical treatment of meningioma, glioma and metastatic disease, particularly breast cancer that is metatastic to the central nervous system.
- Glioma Research Consortium
United States; Sweden; United Kingdom; Denmark; Israel (2008)
Professor Claus is a co-investigator for GLIOGENE, an international, multidisciplinary consortium of glioma researchers. The goal of this consortium is to identify susceptibility genes in high-risk familial brain tumor pedigrees by screening glioma patients within the United States, Europe, and Israel. The hypothesis is that there are specific discoverable genotypes that increase the risk of developing brain tumors. Professor Claus also conducts work with this group to refine treatment algorithms for patients diagnosed with low-grade gliomas.
Education & Training
- Yale University (1988)
- Yale University School of Medicine (1994)
- Yale- New Haven Hospital, General Surgery (1995 - 1996)
- Yale-New Haven Hospital, Neurosurgery (1996 - 2002)
- Brigham and Women's Hospital, Neurosurgery (Oncology) (2002 - 2003)
- Advisory Board Member, National Institutes of Health (9/1/2010)
- Member, Board of Medical Advisors, Acoustic Neuroma Association (10/1/2010 - 9/30/2015)